Back to results
US 2025/0026741 A1Published application
Inhibitors of the oncogenic shp2 phosphatase and uses thereof
AssigneeSanford Burnham Prebys Medical Discovery Institute
InventorsNicholas David Peter COSFORD, Lutz TAUTZ, Dhanya RAVEENDRA-PANICKAR, Darren FINLAY, Lester LAMBERT
Life of this patent
Estimating the term…
Abstract
Described herein are compounds which are inhibitors of oncogenic and wild-type SHP2 and methods of treatment using SHP2 inhibitors.
Claims67
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein,
- R1 is:
- or hydrogen;
- R2 is —H, halogen, —OH, —C(O)N(R12)2, —CN, —COOH, —C(O)NR12N(R12)2, —C(O)R12,
- A is —CH2—, —S—, —O—, —CH2—CH2—, —C(R12)2—, or —C(R12)2—C(R12)2—;
- Y is —O—, —S—, —NH— or —CH═CH—;
- L is a bond, —CH═, or —C(═O)CH═CH—.
- R3 is hydrogen, —OH, —F, —Cl, —CF3, —OCF3, or —Br;
- R4, R5, R6, R7, R8, and R9 are each independently hydrogen, halogen, —OR13, —SR13, —N(R13)2, —NO2, —C(O)OR13, —C(O)N(R13)2, —C(S)OR13, —C(S)SR13, —C(O)SR13, C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkenyl, substituted or unsubstituted C6 aryl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C3-C8 cycloalkenyl, substituted or unsubstituted C3-C8 cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl, or C1-C16 substituted or unsubstituted alkynyl;
- R10 and R11 either together form a substituted or unsubstituted 6 membered aryl ring, or are each independently hydrogen, —OR13, —SR13, —N(R13)2, —NO2, —CN, —C(O)OR13, —C(O)N(R13)2, —C(S)OR13, —C(S)SR13, —C(O)SR13, C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkenyl, substituted or unsubstituted C6 aryl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C3-C8 cycloalkenyl, substituted or unsubstituted C3-C8 cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl, or C1-C16 substituted or unsubstituted alkynyl;
- R12 are each independently hydrogen, halogens, —OH, —CN, —SH, —NO2,
- C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkenyl, substituted or unsubstituted C6 aryl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C3-C8 cycloalkenyl, substituted or unsubstituted C3-C8 cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl, or C1-C16 substituted or unsubstituted alkynyl;
- R13 are each independently C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkenyl, substituted or unsubstituted C6 aryl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C3-C8 cycloalkenyl, substituted or unsubstituted C3-C8 cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl, or C1-C16 substituted or unsubstituted alkynyl;
- wherein
- when R1 is hydrogen, R2 is
- and R3 is —OH;
- when A is —C(R12)2—C(R12)2—, R2 is —C(O)OH and R3 is —OH or R3 is —C(O)OH and R2 is —OH;
- with the proviso that the compound is not a molecule from Table 1.
15 more elements
A compound selected from:
- or a pharmaceutically acceptable salt thereof.
A method of treating cancer comprising administering a therapeutically effective dose of an SHP2 inhibiting compound of Formula Ia:
- or a pharmaceutically acceptable salt thereof, wherein,
- R1 is:
- or hydrogen;
- R2 is selected from the group of:
- —H, halogen, —OH, —C═O—N(R13)2, —CN, —C═O—OH, —C═O—NR13—N(R13)2, —C═O—R12, —C(═O)O—R13, —R12, —O—R13, C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkenyl, substituted or unsubstituted C6 aryl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C3-C8 cycloalkenyl, substituted or unsubstituted C3-C8 cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl, C1-C16 substituted or unsubstituted alkynyl,
- A is —CH2—, —S—, —O—, —CH2—CH2—, —C(R12)2—, or —C(R12)2—C(R12)2—;
- Y is —O—, —S—, —NH— or —CH═CH—;
- L is a bond, —CH═, or —C(═O)CH═CH—.
- R3 is selected from the group of hydrogen, halogens, —C═O—N(R13)2, —CN, —C═O—OH, —C═O—NR13—N(R13)2, —C═O—R12, —C(═O)O—R13, —R12, —O—R13, —OH, —F, —Cl, —CF3, —OCF3, C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkenyl, substituted or unsubstituted C6 aryl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C3-C8 cycloalkenyl, substituted or unsubstituted C3-C8 cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl, or C1-C16 substituted or unsubstituted alkynyl;
- R4, R5, R6, R7, R8, and R9 are each independently hydrogen, halogen, —OR13, —SR13, —N(R13)2, —NO2, —C(O)OR13, —C(O)N(R13)2, —C(S)OR13, —C(S)SR13, —C(O)SR13, C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkenyl, substituted or unsubstituted C6 aryl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C3-C8 cycloalkenyl, substituted or unsubstituted C3-C8 cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl, or C1-C16 substituted or unsubstituted alkynyl;
- R10 and R11 either together form a substituted or unsubstituted 6 membered aryl ring, or are each independently hydrogen, —OR13, —SR13, —N(R13)2, —NO2, —CN, —C(O)OR13, —C(O)N(R13)2, —C(S)OR13, —C(S)SR13, —C(O)SR13, C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkenyl, substituted or unsubstituted C6 aryl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C3-C8 cycloalkenyl, substituted or unsubstituted C3-C8 cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl, or C1-C16 substituted or unsubstituted alkynyl;
- R12 are each independently hydrogen, halogens, —OH, —CN, —SH, —NO2,
- C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkenyl, substituted or unsubstituted C6 aryl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C3-C8 cycloalkenyl, substituted or unsubstituted C3-C8 cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl, or C1-C16 substituted or unsubstituted alkynyl;
- R13 are each independently C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkyl, C1-C16 substituted or unsubstituted alkenyl, substituted or unsubstituted C6 aryl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C3-C8 cycloalkenyl, substituted or unsubstituted C3-C8 cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted heterocycloalkynyl, or C1-C16 substituted or unsubstituted alkynyl;
- with the proviso that the compound is not:
12 more elements
A method of treating cancer comprising administering a therapeutically effective dose of a compound selected from:
- or a pharmaceutically acceptable salt thereof.
A compound selected from:
- or a pharmaceutically acceptable salt thereof.
A compound selected from:
- or a pharmaceutically acceptable salt thereof.
A compound, selected from:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.